Merck (SNSE:MRKCL) - Stock Price, News & Analysis

MRKCL Stock Overview

Merck & Co., Inc. operates as a healthcare company worldwide.

MRKCL fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	1/6
Financial Health	4/6
Dividends	3/6

Rewards

Trading at 47.6% below our estimate of its fair value

Earnings are forecast to grow 25.89% per year

Risk Analysis

Profit margins (0.6%) are lower than last year (24.5%)

Large one-off items impacting financial results

Has a high level of debt

Significant insider selling over the past 3 months

+ 1 more risk

Merck & Co., Inc. Competitors

Johnson & Johnson

NYSE:JNJ

US$360.4b

AstraZeneca

LSE:AZN

UK£176.0b

Novartis

SWX:NOVN

CHF181.8b

Novo Nordisk

CPSE:NOVO B

kr.3.9t

Price History & Performance

Summary of all time highs, changes and price drops for Merck
Historical stock prices
Current Share Price	US$120,487.00
52 Week High	US$130,550.00
52 Week Low	US$86,314.00
Beta	0.40
1 Month Change	1.16%
3 Month Change	10.67%
1 Year Change	54.88%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	102.39%

Recent updates

Shareholder Returns

	MRKCL	CL Pharmaceuticals	CL Market
7D	0%	0%	0%
1Y	54.9%	0%	0%

Return vs Industry: MRKCL exceeded the CL Pharmaceuticals industry which returned -15.4% over the past year.

Return vs Market: MRKCL exceeded the CL Market which returned 17% over the past year.

Price Volatility

Is MRKCL's price volatile compared to industry and market?
MRKCL volatility
MRKCL Average Weekly Movement	4.0%
Pharmaceuticals Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in CL Market	0%
10% least volatile stocks in CL Market	0%

Stable Share Price: MRKCL has not had significant price volatility in the past 3 months.

Volatility Over Time: MRKCL's weekly volatility (4%) has been stable over the past year, but is still higher than 75% of CL stocks.

About the Company

Founded	Employees	CEO	Website
1891	71,000	Rob Davis	www.merck.com

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Merck & Co., Inc. Fundamentals Summary

How do Merck's earnings and revenue compare to its market cap?
MRKCL fundamental statistics
Market cap	CL$305.88t
Earnings (TTM)	CL$347.06b
Revenue (TTM)	CL$57.16t

881.4x

P/E Ratio

5.4x

P/S Ratio

Is MRKCL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MRKCL income statement (TTM)
Revenue	US$60.12b
Cost of Revenue	US$15.92b
Gross Profit	US$44.20b
Other Expenses	US$43.84b
Earnings	US$365.00m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 25, 2024

Earnings per share (EPS)	0.14
Gross Margin	73.53%
Net Profit Margin	0.61%
Debt/Equity Ratio	93.1%

How did MRKCL perform over the long term?

See historical performance and comparison

Dividends

2.4%

Current Dividend Yield

2,030%

Payout Ratio

MRKCL Stock Overview

Rewards

Risk Analysis

Merck & Co., Inc. Competitors

NYSE:JNJ

US$360.4b

LSE:AZN

UK£176.0b

SWX:NOVN

CHF181.8b

CPSE:NOVO B

kr.3.9t

Price History & Performance

Recent News & Updates

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA®? (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer

European Commission Approves Merck’s Keytruda® (Pembrolizumab) Plus Chemotherapy

Merck Provides Update on Phase 3 Keylynk-006 Trial Evaluating Keytruda® (Pembrolizumab) Plus Maintenance Lynparza® (Olaparib) for Certain Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer

Merck Announces Positive Data on V116, Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Merck Announces its KEYTRUDA Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival Versus CRT Alone in Patients with Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Merck Announces Plans to Conduct Clinical Trials of A Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

Recent updates

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA®? (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer

European Commission Approves Merck’s Keytruda® (Pembrolizumab) Plus Chemotherapy

Merck Provides Update on Phase 3 Keylynk-006 Trial Evaluating Keytruda® (Pembrolizumab) Plus Maintenance Lynparza® (Olaparib) for Certain Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer

Merck Announces Positive Data on V116, Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Merck Announces its KEYTRUDA Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival Versus CRT Alone in Patients with Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Merck Announces Plans to Conduct Clinical Trials of A Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Upcoming dividend of US$0.77 per share

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Full year 2023 earnings released: EPS: US$0.14 (vs US$5.73 in FY 2022)

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence

Merck & Co., Inc., Annual General Meeting, May 28, 2024

FDA Grants Priority Review to Merck's Application for Keytruda (Pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

Health Canada Approves Keytruda® in Combination with Trastuzumab and Chemotherapy, as A First-Line Treatment for Patients with Locally Advanced Her2-Positive Gastric or Gastric or Gastroesophageal Junction Adenocarcinoma

Executive VP & General Counsel recently sold CL$3.6b worth of stock

Full year 2023 earnings released: EPS: US$0.14 (vs US$5.73 in FY 2022)

Third quarter dividend of US$0.77 announced

Merck Announces Results from the Phase 3 AMBASSADOR (A031501/KeyNOTE-123 Trial Evaluating KEYTRUDA

Merck Declares Dividend for the Second Quarter of 2024, Payable on April 5, 2024

Merck & Co., Inc. Announces FDA Approves Merck's KEYTRUDA® (Pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients with FIGO 2014 Stage III-IVA Cervical Cancer

Merck Reportedly in Talks to Buy Harpoon Therapeutics

Merck & Co., Inc. Announces Phase 3 Trial Initiations for Four Investigational Candidates from Its Promising Hematology and Oncology Pipeline

FDA Grants Priority Review to Merck's New Biologics License Application for V116

Merck Announces FDA Approves Expanded Indication for KEYTRUDA (pembrolizumab) Plus Padcev for the First-Line Treatment of Adult Patients with Locally Advanced or Metastatic Urothelial Cancer

Merck and Moderna Initiates INTerpath-002, A Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with Keytruda® (Pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer

Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Upcoming dividend of US$0.77 per share at 2.8% yield

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer

Merck & Co., Inc. Announces Management Changes, Effective on December 4, 2023

Merck & Co., Inc. (NYSE:MRK) entered into definitive agreement to acquire an unknown stake in Caraway Therapeutics, Inc. from AbbVie Ventures, Inc., SV Health Investors, LLC,Dementia Discovery LP, Amgen Ventures and Eisai Innovation Inc. for $610 million.